106 related articles for article (PubMed ID: 20126991)
1. Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors.
Pasquini L; Petronelli A; Petrucci E; Saulle E; Mariani G; Scambia G; Benedetti-Panici P; Greggi S; Cognetti F; Testa U
Int J Oncol; 2010 Mar; 36(3):707-13. PubMed ID: 20126991
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
Saulle E; Petronelli A; Pasquini L; Petrucci E; Mariani G; Biffoni M; Ferretti G; Scambia G; Benedetti-Panici P; Cognetti F; Humphreys R; Peschle C; Testa U
Apoptosis; 2007 Apr; 12(4):635-55. PubMed ID: 17252198
[TBL] [Abstract][Full Text] [Related]
3. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
Luster TA; Carrell JA; McCormick K; Sun D; Humphreys R
Mol Cancer Ther; 2009 Feb; 8(2):292-302. PubMed ID: 19174554
[TBL] [Abstract][Full Text] [Related]
4. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
Voortman J; Resende TP; Abou El Hassan MA; Giaccone G; Kruyt FA
Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
[TBL] [Abstract][Full Text] [Related]
5. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
7. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Shanker A; Brooks AD; Tristan CA; Wine JW; Elliott PJ; Yagita H; Takeda K; Smyth MJ; Murphy WJ; Sayers TJ
J Natl Cancer Inst; 2008 May; 100(9):649-62. PubMed ID: 18445820
[TBL] [Abstract][Full Text] [Related]
8. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis.
Brüning A; Burger P; Vogel M; Rahmeh M; Friese K; Lenhard M; Burges A
Invest New Drugs; 2009 Dec; 27(6):543-51. PubMed ID: 19039521
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
Conticello C; Adamo L; Giuffrida R; Vicari L; Zeuner A; Eramo A; Anastasi G; Memeo L; Giuffrida D; Iannolo G; Gulisano M; De Maria R
J Clin Endocrinol Metab; 2007 May; 92(5):1938-42. PubMed ID: 17327374
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.
Steg AD; Burke MR; Amm HM; Katre AA; Dobbin ZC; Jeong DH; Landen CN
Oncotarget; 2014 Aug; 5(16):7065-80. PubMed ID: 25216523
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.
Kahana S; Finniss S; Cazacu S; Xiang C; Lee HK; Brodie S; Goldstein RS; Roitman V; Slavin S; Mikkelsen T; Brodie C
Cell Signal; 2011 Aug; 23(8):1348-57. PubMed ID: 21440622
[TBL] [Abstract][Full Text] [Related]
13. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
[TBL] [Abstract][Full Text] [Related]
14. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
15. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
Tuthill MH; Montinaro A; Zinngrebe J; Prieske K; Draber P; Prieske S; Newsom-Davis T; von Karstedt S; Graves J; Walczak H
Oncogene; 2015 Apr; 34(16):2138-2144. PubMed ID: 24909167
[TBL] [Abstract][Full Text] [Related]
16. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
Seol DW
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):222-5. PubMed ID: 22120628
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
Unterkircher T; Cristofanon S; Vellanki SH; Nonnenmacher L; Karpel-Massler G; Wirtz CR; Debatin KM; Fulda S
Clin Cancer Res; 2011 Jun; 17(12):4019-30. PubMed ID: 21525171
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.
Laussmann MA; Passante E; Hellwig CT; Tomiczek B; Flanagan L; Prehn JH; Huber HJ; Rehm M
J Biol Chem; 2012 Apr; 287(18):14402-11. PubMed ID: 22408249
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex.
Koschny R; Boehm C; Sprick MR; Haas TL; Holland H; Xu LX; Krupp W; Mueller WC; Bauer M; Koschny T; Keller M; Sinn P; Meixensberger J; Walczak H; Ganten TM
J Neuropathol Exp Neurol; 2014 Nov; 73(11):1034-46. PubMed ID: 25289891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]